PMID- 29264260
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 2214-6873 (Print)
IS  - 2214-6873 (Electronic)
IS  - 2214-6873 (Linking)
VI  - 4
DP  - 2016 Apr
TI  - Hyaluronic acid induces the release of growth factors from platelet-rich plasma.
PG  - 27-32
LID - 10.1016/j.asmart.2016.01.001 [doi]
AB  - BACKGROUND/OBJECTIVE: Platelet-rich plasma (PRP) and hyaluronic acid (HA) 
      injection are both therapeutic options for osteoarthritis and chronic 
      tendinopathy. Although several comparative studies on the two have been 
      published, the effects of mixing PRP and HA are not fully understood. The purpose 
      of this study is to investigate the influence of HA on platelets in PRP by 
      measuring releasing growth factors. METHODS: PRP was produced from nine healthy 
      adult volunteers (mean age, 32.8 +/- 2.9 years; range, 29-37) with a commercial 
      separation system. HA of weight-average molecular weight of 50-120 kDa was used. 
      PRP group (PRP 1 mL + phosphate buffered saline 0.2 mL) and PRP + HA group (PRP 
      1 mL + HA 0.2 mL) were incubated at 37 degrees C for 2 hours. The amounts of transforming 
      growth factor beta1 (TGF-beta1) and platelet-derived growth factor (PDGF-AA) released 
      from the PRP and PRP + HA samples were measured on Day 0, Day 3, and Day 5. In 
      addition, the same growth factors on Day 5 were measured for PRP + high HA group 
      (PRP 1 mL + HA 0.6 mL) with five donors. After collecting all of the samples on 
      Day 5, the remaining gels were observed with Giemsa stain. Statistical analyses 
      were performed using paired t tests to compare the PRP and HA groups at each time 
      point, and a one-way analysis of variance (one-way ANOVA) with Tukey post hoc 
      tests was used to compare the PRP, PRP + HA, and PRP + high HA groups. RESULTS: 
      The TGF-beta1 concentrations in the PRP and PRP + HA were 24.3 +/- 7.2 mug/mL and 
      22.4 +/- 1.8 mug/mL (p = 0.689) on Day 0, 17.2 +/- 13.9 mug/mL and 25.4 +/- 7.1 mug/mL 
      (p = 0.331) on Day 3, and 12.7 +/- 10.5 mug/mL and 33.7 +/- 8.3 mug/mL (p = 0.034) on 
      Day 5. The TGF-beta1 concentrations on Day 5 were 24.1 +/- 5.2 mug/mL (PRP group), 
      28.3 +/- 2.4 mug/mL (PRP + HA), and 31.9 +/- 4.8 mug/mL (PRP + high HA; one-way ANOVA: 
      p = 0.003; post hoc PRP vs. PRP + HA: p = 0.016). The PDGF-AA concentrations in 
      the PRP and PRP + HA groups were 2.30 +/- 1.21 mug/mL and 2.32 +/- 0.79 mug/mL 
      (p = 0.931) on Day 0, 2.03 +/- 0.53 mug/mL and 2.13 +/- 0.73 mug/mL (p = 0.500) on Day 
      3, and 1.51 +/- 0.40 mug/mL and 2.00 +/- 0.52 mug/mL (p = 0.003) on Day 5. The PDGF-AA 
      concentrations were 1.48 +/- 0.46 mug/mL (PRP group), 1.94 +/- 0.57 mug/mL (PRP + HA), 
      and 2.69 +/- 0.70 mug/mL (PRP + high HA; one-way ANOVA: p = 0.0002; PRP vs. PRP + 
      high HA: p = 0.002; PRP + HA vs. PRP + high HA: p = 0.011) on Day 5. The PRP 
      showed larger coagulated masses than the PRP + HA. The high concentration HA 
      group had the smallest coagulated mass of all of the group. CONCLUSION: The 
      levels of growth factors released by PRP on Day 5 were increased by the addition 
      of HA. A mixture of PRP and HA may be a more effective therapy than PRP or HA 
      alone for osteoarthritis and tendinopathy.
FAU - Iio, Kohei
AU  - Iio K
AD  - Department of Orthopaedic Surgery, Mutsu General Hospital, Aomori, Japan.
AD  - Department of Orthopaedic Surgery, Hirosaki University Graduate School of 
      Medicine, Aomori, Japan.
FAU - Furukawa, Ken-Ichi
AU  - Furukawa KI
AD  - Department of Pharmacology, Hirosaki University Graduate School of Medicine, 
      Aomori, Japan.
FAU - Tsuda, Eiichi
AU  - Tsuda E
AD  - Department of Orthopaedic Surgery, Hirosaki University Graduate School of 
      Medicine, Aomori, Japan.
FAU - Yamamoto, Yuji
AU  - Yamamoto Y
AD  - Department of Orthopaedic Surgery, Hirosaki University Graduate School of 
      Medicine, Aomori, Japan.
FAU - Maeda, Shugo
AU  - Maeda S
AD  - Department of Orthopaedic Surgery, Hirosaki University Graduate School of 
      Medicine, Aomori, Japan.
FAU - Naraoka, Takuya
AU  - Naraoka T
AD  - Department of Orthopaedic Surgery, Hirosaki University Graduate School of 
      Medicine, Aomori, Japan.
FAU - Kimura, Yuka
AU  - Kimura Y
AD  - Department of Orthopaedic Surgery, Hirosaki University Graduate School of 
      Medicine, Aomori, Japan.
FAU - Ishibashi, Yasuyuki
AU  - Ishibashi Y
AD  - Department of Orthopaedic Surgery, Hirosaki University Graduate School of 
      Medicine, Aomori, Japan.
LA  - eng
PT  - Journal Article
DEP - 20160228
PL  - Singapore
TA  - Asia Pac J Sports Med Arthrosc Rehabil Technol
JT  - Asia-Pacific journal of sports medicine, arthroscopy, rehabilitation and 
      technology
JID - 101648546
PMC - PMC5730656
OTO - NOTNLM
OT  - growth factor
OT  - hyaluronic acid
OT  - platelet-derived growth factor
OT  - platelet-rich plasma
OT  - transforming growth factor-beta1
EDAT- 2016/02/28 00:00
MHDA- 2016/02/28 00:01
PMCR- 2016/02/28
CRDT- 2017/12/22 06:00
PHST- 2015/09/05 00:00 [received]
PHST- 2015/11/25 00:00 [revised]
PHST- 2016/01/04 00:00 [accepted]
PHST- 2017/12/22 06:00 [entrez]
PHST- 2016/02/28 00:00 [pubmed]
PHST- 2016/02/28 00:01 [medline]
PHST- 2016/02/28 00:00 [pmc-release]
AID - S2214-6873(16)00002-9 [pii]
AID - 10.1016/j.asmart.2016.01.001 [doi]
PST - epublish
SO  - Asia Pac J Sports Med Arthrosc Rehabil Technol. 2016 Feb 28;4:27-32. doi: 
      10.1016/j.asmart.2016.01.001. eCollection 2016 Apr.